ABSTRACT Alpha-synuclein is an intrinsically disordered, highly dynamic protein that pathogenically aggregates into inclusion structures called Lewy bodies, in several neurogenerative

diseases termed synucleinopathies. Despite its importance for understanding disease, the oligomerization status of alpha-synuclein in healthy cells remains unclear. Alpha-synuclein may exist

predominantly as either a monomer or a variety of oligomers of different molecular weights. There is solid evidence to support both theories. Detection of apparent endogenous oligomers are

intimately dependent on vesicle and lipid interactions. Here we consider the possibility that apparent endogenous alpha-synuclein oligomers are in fact conformations of membrane-bound

to toxic oligomers. The distinction is important, because it clarifies the biological origin of synucleinopathy. We suggest that a monomer-only, lipid-centric view of endogenous

alpha-synuclein aggregation can explain how alpha-synuclein pathology is triggered, and that the interactions between alpha-synuclein and lipids can represent a target for therapeutic

intervention. This discussion is well-timed due to recent studies that show lipids are a significant component of Lewy pathology. SIMILAR CONTENT BEING VIEWED BY OTHERS A SERIES OF HELICAL

Α-SYNUCLEIN FIBRIL POLYMORPHS ARE POPULATED IN THE PRESENCE OF LIPID VESICLES Article Open access 19 August 2020 THE 3D STRUCTURE OF LIPIDIC FIBRILS OF Α-SYNUCLEIN Article Open access 10

November 2022 SMALL SOLUBLE Α-SYNUCLEIN AGGREGATES ARE THE TOXIC SPECIES IN PARKINSON’S DISEASE Article Open access 20 September 2022 INTRODUCTION Alpha-synuclein (αSyn) is an intrinsically

disordered, highly flexible protein, which plays an important role in the pathogenesis of several neurodegenerative diseases cumulatively referred to as synucleinopathies. In different

synucleinopathies, neurons and/or glia bare the hallmark intracellular deposits of filamentous αsyn1 but the origin of this pathology remains unclear. αSyn oligomers with β-sheet structure

(αsynO-β) are toxic to cells, possibly through physical disruption of cellular membranes.2,3 αSynO-β/preformed fibrils (PFFs) generated in vitro or isolated from the brains of patients

developing synucleinopathies can “seed” aggregates, especially in transgenic rodent models overexpressing αsyn,4 and initiate a toxic cascade reminiscent of that seen in disease.5,6,7

However, not all oligomers are believed to be bad actors, as evidence suggests that various oligomers may not only exist in the cell but also have normal cellular functions.8,9,10 Indeed,

some conformers of αsynO-β do not seed pathology and are non-toxic.11,12,13 Functional endogenous oligomers have been controversial, as their existence has been both confirmed and refuted by

carefully executed studies.8,14,15 Are there benign αsyn oligomers that have normal cellular functions, and if so, how do they transition to toxic αsynO-β? Here, in this short review, we

discuss how lipid–αsyn interactions might help explain the observation of apparent endogenous non-toxic oligomers and highlight alternative models that are monomer-centric. Furthermore, we

will extend this viewpoint to consider its implications for synucleinopathy pathogenesis. There has been substantial work done in this area and several exhaustive reviews on lipid–αsyn

interactions16,17,18,19,20,21 and oligomerization22,23 are available; hence, for the sake of clarity, we will not comprehensively discuss the literature. BIOLOGY OF LIPIDS IN

NEURODEGENERATIVE DISEASE The brain is ~60% lipids by weight.24 Lipids have diverse cellular functions in biology including cell signaling, energy storage, and structural partitioning.25

Phospholipids contain amphipathic characteristics with a charged hydrophilic phosphate group and a carbon chain of varying lengths.25 Phospholipids spontaneously form bilayer structures in

aqueous solutions that are the basis of cellular membranes. Lipids have not been as extensively studied as proteins in vivo, possibly because of their hydrophobicity, chemical complexity,

and the fact that they are not gene products.25 However, lipids are crucial for cellular function and are implicated in several neurodegenerative diseases including synulceinopathies.26

Recent technological advances with lipodomic analysis have furthered the study of lipids.27,28,29,30 Current lipodomic analyses, however, are focused on whole-cell lysates and therefore

insensitive to cellular spatial and temporal dimensions, which are crucial for understanding lipid function.25 ΑSYN–VESICLE MEMBRANE INTERACTIONS Shortly following the discovery of αsyn in

Lewy pathology,31 the lipid-binding properties of asyn were documented and the significance of disease-causing point mutations in lipid-binding domains was recognized.32 Indeed, one of the

earliest histochemical descriptions of Lewy bodies noted that they stain positively for phospholipids, particularly sphingomyelin.33 Since then, interactions between αsyn and vesicle lipids

have been implicated in the initial generation of synucleinopathy.16,17,18,19,34,35,36 The hypothesis that lipids control pathological αsyn aggregation primarily stems from observations that

lipids/vesicles influence aggregation kinetics in vitro,34,37,38,39,40 and that disease-related missense mutations of _SNCA_ alter residues within the N-terminal lipid-binding domain of

αsyn.41,42,43,44,45,46 αSyn may redistribute to lipid compartments early in disease pathogenesis.36 Several disease-causing αsyn mutants abnormally associate with intracellular vesicles and

lipid droplets,47,48 and dyshomeostasis of intracellular lipids are likely an early molecular event preceding pathology formation.49 The key to pathogenesis lies within the lipid-binding

domain of αsyn. αSyn binding to vesicular membranes is important, because it influences oligomerization and pathological aggregation. Evidence suggests that non-pathological αsyn is involved

with vesicular dynamics in cells9,18,50,51,52,53,54,55 and regulation of the presynaptic vesicle pool.56,57 αSyn–lipid interactions may have a vesicle tethering function. It has been

proposed that the broken α-helical N-terminus can function to tether intracellular vesicles via a “double-anchor” mechanism.58,59,60,61 The biological significance of αsyn-mediated

clustering is unknown; however, it could serve to promote the exchange of lipids between adjacent vesicles62 and possibly promote vesicle fusion.56,57,58,62,63,64 αSyn preferentially binds

to membranes with lipid-packing defects65,66,67,68 and high curvature.69,70,71,72 In the neurons, αsyn is densely clustered around intracellular vesicles and vesicular tubule structures,

most prominently at the nerve terminal.73 When incubated with small (~10–30 nm) unilamaller vesicles, the N-terminal of αsyn adopts an extended α-helical conformation as it coats the

vesicular surface and a broken α-helical conformation when interacting with micelles.59,74,75,76,77,78,79,80 The interaction between the N-terminus of αsyn with lipid membranes is driven by

electrostatic interactions between positively charged residues and lipid phosphate head group.81 When membrane bound, the N-terminus residues (1–26) of αsyn rigidly bind to the membrane and

the internal segment (residues 26–97) acts to sense lipid properties and regulates binding affinity.82 Interestingly, the hydrophobic stretch of residues 71–82 are required for pathological

aggregation of αsyn83 and, therefore, lipid-sensing properties of αsyn and pathological aggregation occur through the same functional domain. It is not clear whether mutation of the

N-terminus results in a toxic gain of function or loss of function. Many cellular functions have been attributed to αsyn and membrane interactions, including soluble N‐ethylmaleimide

sensitive factor attachment protein receptor (SNARE) complex assembly and exocytosis; however, the exact cellular function of αsyn remains unclear.9,50,84 αSyn interacts with SNARE proteins

at the vesicle surface.85,86,87,88 αSyn binding to membranes promotes SNARE complex formation and may function as a SNARE chaperone protein.9,88,89 Vesicular membrane-binding promotes the

oligomerization of αsyn.9 In vitro phospholipids can also increase the rate of pathological aggregation (i.e., β-sheet confirmations) by decreasing lag time of primary nucleation.37,90 The

effect of lipids on αsyn aggregation is dependent on lipid to protein ratio, with a low ratio promoting aggregation and higher ratio being inhibitory.74,91 This bimodal phenomenon probably

results from a lack of monomer available for oligomer elongation when the lipid ratio is too high. Interestingly, increasing αsyn expression, presumably shifting the intracellular lipid to

protein ratio, promotes aggregation of αsyn in cells. Notably, it has been hypothesized that reducing monomeric αsyn is an important therapeutic target.92,93,94 A confusing aspect to the

literature is that binding of αsyn to membranes has been reported to both inhibit95,96,97 and to promote αsyn aggregation.39,47 This may be due to differences in assay conditions between

studies, such as membrane lipid composition and αsyn concentration. Indeed, recent studies using lipodomics implicated specific fatty acid oleic acid in the pathogenesis of Parkinson’s

disease.49 In the model proposed by Fanning and colleagues49, soluble αsyn binds to oleic acid, effectively sequestering the monomer to lipid membranes and ultimately culminating in

pathological aggregate formation. As they also observed an increase in oleic acid in response to αsyn overexpression, there may be a toxic lipid dyshomeostatis that preceeds aggregate

formation. Their results suggest a complex origin of synucleinopathy where both lipid metabolism and αsyn are central players. αSyn may have a more generalized cellular function as an

effector of lipid dynamics, and not as a factor of a specific subprocess or pathway. To highlight this concept, consider the curious relationship between αsyn and erythropoiesis (i.e., red

blood cell differentiation) for which others have hypothesized αsyn that may have an underlying redundant mechanism in the two cells of different linage.98 αSyn is highly expressed in

erythrocytes under the control of transcription factor GATA1.99,100 During the terminal step of erythropoiesis, α-syn expression dramatically increases and remains elevated in the mature

erythrocyte.98 αSyn is then found associated with phospholipids and vesicle membranes in the mature erythrocyte.101 Thus, which of the proposed cellular functions does αsyn perform during

erythropoiesis? One likely explanation is that αsyn plays a role in the dramatic intracellular lipid organization, analogous to asymmetric cytokinesis, which occurs prior to the phenomenon

of enucleation. Enucleation is the process by which organelles are condensed and extruded from the cell to form a mature erythrocyte. Indeed, just prior to enucleation αsyn can be found

associated with lipids of the cell, particularly the nucleus and ER, which are key players in enucleation. αSyn accumulates at the site of nuclear extrusion,102 suggesting it is directly

involved with enucleation lipid dynamics. Concurrently, SNARE machinery is decreased in the erythrocyte, suggesting that the potential involvement of αsyn in lipid dynamics during

enucleation is independent of hypothesized SNARE functions.103 However, if αsyn is involved in this cellular phenomenon, it is non-essential or interchangeable with beta or gamma synucleins,

as only minor phenotypic abnormalities of erythrocytes are observed in α-syn-knockout models.99 SOLUBLE OLIGOMERS DEVOID OF LIPID There is good evidence of a naturally occurring metastable

soluble αsyn oligomer (i.e., tetramer) that is devoid of vesicle/lipid binding.8 However, the existence of a soluble αsyn tetramer is based mostly on results from crosslinking

experiments.8,48,104,105,106 The interpretation of crosslinking experiments is non-trivial. αSyn tetramers are captured when using a permissive chemical cross-linker with spacer arm length

(DSG spacer arm length 7.7 Å) and perhaps not with a shorter spacer arm (formalin spacer arm length ~2 Å).107 A milieu of progressively larger oligomers are formed and captured even when

purified recombinant αsyn is incubated with glutaraldehyde.108 The successful detection of an αsyn tetramer in tissues and cells is dependent on sample preparation conditions and can be

detected when cells remain intact prior to crosslinking or when tissue lysates are kept highly concentrated.107 Indeed, purification of αsyn prevents the detection of a soluble tetramer

further suggesting a cofactor is required and this factor is likely of lipid origin.109 Although the question remains which lipid cofactor might be responsible for the tetramer formation,

the tetramer and αsyn–lipid interactions are inextricably linked. This is highlighted when recently a transgenic mouse model (called “3K”) of tetramer deficiency was generated by introducing

3E– > K mutations in αsyn’s lipid-binding N-terminus.48 These 3K mice exhibit aggressive αsyn aggregation, loss of an apparent tetramer, and a motor phenotype that has some semblance to

Parkinson’s disease. The lipid-binding domain was mutated in the 3K mice and correspondingly lipid interactions were enhanced48 and similar to what was observed with similar mutations in

cells.110 In both mice and cells, mutated 3K αsyn clustered around vesicles and intact tissue crosslinking captured less soluble tetramer.48,106,110 Was this due to less tetramer or

alternatively less soluble tetramer? The results could be explained either way, but if the captured αsyn species is truly an insoluble tetramer, one would expect less detection in the

soluble fraction, as the authors observed. Indeed, the results appear to fit a scenario where folding on the vesicular membrane is driving αsyn pathology without the need for a soluble

tetramer. (Fig. 1) Detection of endogenous oligomers, including the tetramer, could be explained by compartmentalized αsyn residing on the vesical membrane (Fig. 1). Membrane interactions

occur through electrostatic forces between positively charged lysine residues of αsyn and negatively charge phosphate group of lipids.41,75,81,111 Interestingly, the same crosslinking

chemicals used to capture tetramers chemically modify lysine side chains of αsyn and neutralize their charge.112 Chemically modifying the lysine side chains during tissue crosslinking would

presumably disrupt membrane binding, because it neutralizes the required electrostatic charge of lysine residues. Therefore, captured oligomers would dissociate from the membrane and would

be detected in the soluble fraction, producing the characteristic gel-shift of the αsyn tetramer.106 To highlight this concept, the neutralization of αsyn charge by chemical cross-linkers is

routinely used to enhance the retention of αsyn on polyvinylidene difluoride membranes during western blotting protocols.112 Together, adjacent αsyn molecules bound to intracellular vesicle

surfaces (i.e., compartmentalized) might disassociate into the soluble fraction once chemically modified by the crosslinking reagent. This phenomenon would also help explain why the soluble

tetramer has similar intermolecular n-terminal structure as the membrane-bound form. The apparent soluble tetramer may be stabilized by covalent bonds formed in the oxidative environment of

the erythrocyte (i.e., the source from which it was originally isolated). Biochemical characterization of a putative αsyn tetramer was mostly done using erythrocyte derived αsyn.8

Erythrocytes have millimolar concentrations of hemoglobin. Hemoglobin oxidatively catalyzes the formation of intramolecular dityrosine bonds resulting in a mixture of αsyn dimers and

tetramers.113 Dityrosine crosslink formation occurs rapidly113,114 and would likely occur to some extent during αsyn purification from erythrocytes. αSyn in erythrocytes associates with

vesicles101,102 and stable dityrosine αsyn occurs in clinical blood samples.115 Together, it is probable that stable αsyn oligomers isolated from erythrocytes are due to oxidative

crosslinking of adjacent αsyn molecules bound to vesicle membranes. Heat denaturation irreversibly abolished the tetramers α-helix structure, indicating that the captured configuration was

not in equilibrium but instead was a stabilized structure originating from the tissue (i.e., vesicle bound). Lipid binding of the tetramer was enhanced when compared with the monomer,

further suggesting it retained a lipid-binding confirmation.8 Removal of lipids with Lipodex 1000 did not affect the tetramer detection, suggesting the tetramer was not associated with any

stabilizing lipid structure. Stabilization of small oligomers via oxidative crosslinking can prevent progressive aggregation and might explain why the stable tetramer appears to resist

aggregation.8,116 Together, it is likely to be that the stable soluble αsyn tetramer purified from erythrocyte is a covalently stabilized membrane-bound confirmation similar to that captured

using exogenous crosslinking agents. Soluble αsyn oligomers have been detected using several imaging techniques. Förster resonance energy transfer (FRET) is a powerful technique used to

determine intermolecular distances between molecules with 1–2 nm spatial resolution.117 FRET has been employed to study various aspects of αsyn oligomerization mostly in

vitro9,77,118,119,120 but also ex vivo121 and in vivo.122 In vitro, purified αsyn forms distinct oligomer conformers, which then can spontaneously convert to protease resistant and toxic

αsynO-β.12 Biomolecular fluorescence complementation (BiFC) technique uses fluorescent constructs to determine protein–protein interaction. BiFC constructs have been used to study αsyn

aggregation in vivo;123,124 however, the resolution of this technique cannot differentiate between small oligomers and complex formation (i.e., membrane bound). The method detects diffuse

staining in neurons lacking pathology, suggesting either small aggregates or close association of αsyn molecules normally within the cytosol.124 αSyn comes into close proximity around

synaptic vesicles and possibly forms multimers on the membrane.15 Other BiFC techniques employing photoactivatable fluorescent molecules can increase the spatial resolution to several

nanometers,125 but this type of imaging has yet to be done with αsyn. SOLUBLE DISORDERED MONOMER DEVOID OF LIPID There is also good evidence that αsyn exists predominantly as an

intrinsically disordered monomer in the cytosol.10,14,126,127,128,129,130 αSyn purified from _Escherichia coli_ behaves as an intrinsically disordered protein with a large stokes radius,129

which may be why monomeric αsyn appears to have greater mass in some assays.126 Non-denaturing purification procedures from several tissue sources also produce a disordered monomeric

αsyn.126 A disordered soluble monomer has been observed directly using in-cell nuclear magnetic resonance (NMR) imaging techniques.14 Specifically, investigators transfected cells with

recombinant αsyn labeled with 15N isotope to monitor individual αsyn molecules within the living cells. Results showed that the majority of monomeric αsyn maintained a disordered

confirmation in the cell, while becoming slightly more compact than in free solution, probably due to molecular crowding.14 The compact structure observed in vivo likely prevents spontaneous

aggregation in the cytosol.131 Although this is compelling evidence that the majority of αsyn in the cell occurs as a disordered monomer, the result does not rule out the existence of a

tetramer. A tetramer that existed at low concentration would not be detected and it is possible that the recombinant αsyn behaved dissimilarly to endogenous αsyn. Importantly, this study

demonstrated that the majority of αsyn in the cell is cytosolic and monomeric, and suggests that membrane interactions are likely transient and highly dependent on local environment (e.g.,

nerve terminal). Correspondingly, it would be interesting if αsyn persists as a monomer at axon terminals where it’s vesicle interactions are more prominent than in the cell body.73,132 The

α-helix conformation αsyn was recently described in HELA cells using FRET, where it was demonstrated that αsyn assumes several confirmations when interacting with vesicle surfaces.133

Considered together, the majority of αsyn in the cell exists as a relatively compact disordered monomer and adopts an α-helix structure when interacting with vesicle membranes. The native

state of αsyn may not include an oligomer, whether free and soluble, or vesicle bound. ABERRANT VESICLE BINDING PROGRESSES TO PATHOLOGY Assuming monomeric αsyn is interacting with vesicle

membranes, and remains monomeric at the vesicle surface under normal circumstances, how might pathology begin? (Fig. 2). One possible scenario involves vesicle surfaces acting as

two-dimensional (2D) reactors that promote pathogenic intermolecular interactions of αsyn.91,134,135,136 In the cystosol, αsyn remains monomeric and in a slightly compact configuration.

Transient interactions with vesicle surfaces induce a conformational shift, but not necessarily oligomerization, and concentrate αsyn molecules on the vesicle surface. This focal point on

the vesicle surface is where opposing αsyn molecules bind and might serve as the molecular origins for Lewy pathology. Numerous cellular and genetic factors converge at this focal point in

such a way that creates an environment conducive for the initiation of pathogenic αsyn aggregation. Studies using sonicated αsyn PFFs suggest that once the αsynO-β is present, progressive

aggregation and toxicity follow.7,137 Yet, studies that utilize PFF’s to assess pathology are bypassing pathology generation and may be recapitulating downstream pathological events.

Therefore, the use of PFF’s to study synucleinopathy is likely to give valuable insight into the progression of these diseases and perhaps are not suitable to study the initiation of the

disease. At the membrane, αsynO-β might act similar to a “molecular shovel” inserting itself into the membrane with destructive, toxic, consequences.2,138 Together with lipid/vesicle

interactions at the center of αsyn function, a route to pathophysiology might be the collapse of clustered lipids/vesicles into a pathological inclusion. Similar to a massive star

transitioning to a black hole, at some point pathological αsyn and lipids form a critically dense structure, and compact to form a Lewy body. Interestingly, the architecture of the Lewy

pathology supports this interpretation.139,140,141,142,143,144 Neuropathological examination of patient brains shows a mixture of αsyn staining in neurons that consist of a pale diffuse,

punctate irregular shape (i.e., uneven distribution), discrete body (i.e., pale body), and a massive dense structure with a pale core (i.e., Lewy body).139 These structures have been

hypothesized to be snapshots of a pathological process with Lewy bodies being the result. Indeed, pale bodies contain a mixture of granular and vesicular structures and are often found near

mature LB.141,145 Using a lipid centric view, punctate irregular “early” pathology might represent the initial vesicle clustering48 or lipid droplet formation47 before the characteristic

pathology develops. Overexpression of αsyn in yeast models produces lipid only inclusions, lacking the filamentous αsyn that is the hallmark of synucleinopathies.146 Lipids have been

identified as a core component of Lewy pathology33,147,148 but this has largely been ignored and the pathology is often considered “proteinaceous.” Recent work by Shahmoradian and

colleagues149 provided substantial evidence that Lewy pathology consists of compacted lipid components from a variety of organelles with αsyn oligomers interspersed. Their work strongly

suggests that Lewy pathology is actually an inclusion of fragmented lipids, for which αsyn–lipid interactions play a causative role. Ultrastructural characterization of Lewy pathology showed

tubule vesicular, fragmented membranous, and mixed lipid–protein structures, all of which can be formed from αsyn interactions with vesicle membranes. Electron dense structures, consistent

with lysosomes, were also observed throughout Lewy pathology.149 Lysosomes are central mediators of lipid metabolism150 and the conspicuous presence of lysosomes surrounded by fragmented

membrane structures strongly suggests a deficit in lysosomal/autophagic pathways, specifically the removal of lipid membranes. Large-scale genome-wide association studies have implicated

lysosomal/autophagy pathway in several neurodegerative diseases, including synucleinopathies.151,152 A lipid-centric view of Lewy pathology is transformative in that it helps unify and

identify disease-causing pathology of several molecular origins. Several neurodegenerative diseases are currently characterized by protein aggregation, when instead we may be missing the

lipid components that are the core of the pathology. For example, clinical cases resembling synucleinopathies are documented without the presence of Lewy pathology (e.g., Parkin mutations

with early-onset Parkinson’s disease), as measured by αsyn staining.153 The presence of lipid inclusions in the absence of αsyn are not generally considered when examining patient tissues.

DETERMINING ΑSYN–LIPIDS INTERACTIONS IN LIVING CELLS αSyn interactions with lipids and vesicles has been investigated mostly in vitro and needs to be characterized in living cells. There are

several promising strategies to start understanding lipid–αsyn interactions. The first strategy uses synthetic bifunctional lipids to directly determine lipid–protein interactions.154,155

This strategy offers flexibility with analysis and offers unambiguous evidence of direct αsyn–lipid interactions in vivo. Captured lipid–αsyn molecules can be subsequently labeled or

purified for downstream analysis. Labeling the structures will help determine where αsyn–lipid interactions are most relevant in the cell. Purification of the structures with subsequent

analysis by liquid chromatography–mass spectrometry could determine specific αsyn proteoforms involved with pathological lipid interactions, as well as global analysis of other proteins that

are involved. However, the drawback to this strategy is the investigator can only assess one specific lipid species at a time and a synthetic bifunctional lipid must be available or

developed for application. Recently, a bifunctional analog of glucosylceramide, a lipid implicated in synucleinopathy,156 has become commercially available and could aid in these studies. A

shotgun lipidomic analysis may also be useful, but because of the complexity of whole-cell lipid determination, the data may not give insight into the localized αsyn–lipid interactions that

precede pathology formation. Recently, a shotgun lipodomic analysis was conducted on various αsyn mutant models and αsyn was found to have an effect on lipid metabolism.49 However, it is

difficult to draw distinct conclusions or find drug targets based on the description of a total lipid species. The resulting information is most useful in implicating lipid metabolism or

catabolism pathways, and not the characterization of the specific localized lipids that may be involved with initiating pathology. To find a disease-relevant target, a focused lipodomic

approach looking at specific organelles, or better yet, early Lewy pathology, will be the most illuminating. Lipodomic arrays can also be used to screen many lipid–protein interactions;

however, they have the disadvantage of not representing in vivo binding conditions. A key question remains: at what point during its interaction with cytoplasmic membranes and extracellular

vesicles does αsyn adopt a pathological confirmation? To answer this question, one needs to consider the membrane as a chemical reactor favoring molecular encounters.134 This is the

consequence that restrains monomeric or low-molecular-weight oligomeric αsyn diffusion from a three-dimensional to a 2D space upon interaction with the plasma membrane or extracellular

vesicles plane. CONCLUSIONS Evidence for a soluble αsyn oligomer might be best explained by folding intermediates on the plasma or vesicle membranes that remain soluble for subsequent

extraction and detection. This interpretation does not require a soluble functional oligomer and seems to fit much of the experimental data. The distinction between a soluble native oligomer

and vesicle-bound oligomers/folding intermediates is important, because it clarifies the origins of pathological aggregation of αsyn. With this perspective, determining the molecular

details of αsyn–vesicle/lipid interactions is important for understanding the endogenous origins of synucleinopathy. Although there is consensus that aggregation of αsyn is associated with

neurological disease, the precise molecular origin of the aggregate pathology remains a mystery. REFERENCES * McCann, H., Stevens, C. H., Cartwright, H. & Halliday, G. M.

Alpha-synucleinopathy phenotypes. _Parkinsonism Relat. Disord._ 20, S62–S67 (2014). Article  PubMed  Google Scholar  * Fusco, G. et al. Structural basis of membrane disruption and cellular

toxicity by alpha-synuclein oligomers. _Science_ 358, 1440–1443 (2017). Article  CAS  PubMed  Google Scholar  * Froula, J. M. et al. Defining alpha-synuclein species responsible for

Parkinson disease phenotypes in mice. _J. Biol. Chem._ https://doi.org/10.1074/jbc.RA119.007743 (2019). Article  PubMed  PubMed Central  Google Scholar  * Thakur, P. et al. Modeling

Parkinson’s disease pathology by combination of fibril seeds and alpha-synuclein overexpression in the rat brain. _Proc. Natl Acad. Sci. USA_ 114, E8284–E8293 (2017). Article  CAS  PubMed 

PubMed Central  Google Scholar  * Luk, K. C. et al. Exogenous alpha-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. _Proc. Natl Acad. Sci.

USA_ 106, 20051–20056 (2009). Article  CAS  PubMed  PubMed Central  Google Scholar  * Volpicelli-Daley, L. A. et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to

synaptic dysfunction and neuron death. _Neuron_ 72, 57–71 (2011). Article  CAS  PubMed  PubMed Central  Google Scholar  * Luk, K. C. et al. Intracerebral inoculation of pathological

alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice. _J. Exp. Med._ 209, 975–986 (2012). Article  CAS  PubMed  PubMed Central  Google Scholar  *

Bartels, T., Choi, J. G. & Selkoe, D. J. Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. _Nature_ 477, 107–110 (2011). Article  CAS 

PubMed  PubMed Central  Google Scholar  * Burre, J., Sharma, M. & Sudhof, T. C. Alpha-synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex

formation. _Proc. Natl Acad. Sci. USA_ 111, E4274–4283 (2014). Article  CAS  PubMed  PubMed Central  Google Scholar  * Burre, J. et al. Properties of native brain alpha-synuclein. _Nature_

498, E4–E6 (2013). discussion E6–E7. Article  CAS  PubMed  PubMed Central  Google Scholar  * Winner, B. et al. In vivo demonstration that alpha-synuclein oligomers are toxic. _Proc. Natl

Acad. Sci. USA_ 108, 4194–4199 (2011). Article  CAS  PubMed  PubMed Central  Google Scholar  * Cremades, N. et al. Direct observation of the interconversion of normal and toxic forms of

alpha-synuclein. _Cell_ 149, 1048–1059 (2012). Article  CAS  PubMed  PubMed Central  Google Scholar  * Forloni, G., Artuso, V., La Vitola, P. & Balducci, C. Oligomeropathies and

pathogenesis of Alzheimer and Parkinson’s diseases. _Mov. Disord._ 31, 771–781 (2016). Article  CAS  PubMed  Google Scholar  * Theillet, F. X. et al. Structural disorder of monomeric

alpha-synuclein persists in mammalian cells. _Nature_ 530, 45–50 (2016). Article  CAS  PubMed  Google Scholar  * Wang, L. et al. alpha-synuclein multimers cluster synaptic vesicles and

attenuate recycling. _Curr. Biol._ 24, 2319–2326 (2014). Article  CAS  PubMed  PubMed Central  Google Scholar  * Galvagnion, C. The role of lipids interacting with alpha-synuclein in the

pathogenesis of Parkinson’s disease. _J. Parkinsons Dis._ 7, 433–450 (2017). Article  CAS  PubMed  Google Scholar  * Suzuki, M., Sango, K., Wada, K. & Nagai, Y. Pathological role of

lipid interaction with alpha-synuclein in Parkinson’s disease. _Neurochem. Int._ 119, 97–106 (2018). Article  CAS  PubMed  Google Scholar  * Snead, D. & Eliezer, D. Alpha-synuclein

function and dysfunction on cellular membranes. _Exp. Neurobiol._ 23, 292–313 (2014). Article  PubMed  PubMed Central  Google Scholar  * Alza, N. P., Iglesias Gonzalez, P. A., Conde, M. A.,

Uranga, R. M. & Salvador, G. A. Lipids at the crossroad of alpha-synuclein function and dysfunction: biological and pathological implications. _Front. Cell. Neurosci._ 13, 175 (2019).

Article  PubMed  PubMed Central  Google Scholar  * O’Leary, E. I. & Lee, J. C. Interplay between alpha-synuclein amyloid formation and membrane structure. _Biochimica et biophysica

acta_. _Biochim. Biphys. Acta Proteins Proteom._ 1867, 483–491 (2019). Article  CAS  Google Scholar  * Alecu, I. & Bennett, S. A. L. Dysregulated lipid metabolism and its role in

alpha-synucleinopathy in Parkinson’s disease. _Front. Neurosci._ 13, 328 (2019). Article  PubMed  PubMed Central  Google Scholar  * Bengoa-Vergniory, N., Roberts, R. F., Wade-Martins, R.

& Alegre-Abarrategui, J. Alpha-synuclein oligomers: a new hope. _Acta Neuropathol._ 134, 819–838 (2017). Article  CAS  PubMed  PubMed Central  Google Scholar  * Lashuel, H. A., Overk, C.

R., Oueslati, A. & Masliah, E. The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. _Nat. Rev. Neurosci._ 14, 38–48 (2013). Article  CAS  PubMed  PubMed

Central  Google Scholar  * O’Brien, J. S. & Sampson, E. L. Lipid composition of the normal human brain: gray matter, white matter, and myelin. _J. Lipid Res._ 6, 537–544 (1965). PubMed

  Google Scholar  * Muro, E., Atilla-Gokcumen, G. E. & Eggert, U. S. Lipids in cell biology: how can we understand them better? _Mol. Biol. Cell_ 25, 1819–1823 (2014). Article  PubMed 

PubMed Central  Google Scholar  * Adibhatla, R. M. & Hatcher, J. F. Role of lipids in brain injury and diseases. _Future Lipidol._ 2, 403–422 (2007). Article  CAS  PubMed  PubMed Central

  Google Scholar  * Brugger, B. Lipidomics: analysis of the lipid composition of cells and subcellular organelles by electrospray ionization mass spectrometry. _Annu. Rev. Biochem._ 83,

79–98 (2014). Article  PubMed  CAS  Google Scholar  * Lydic, T. A. & Goo, Y. H. Lipidomics unveils the complexity of the lipidome in metabolic diseases. _Clin. Transl. Med._ 7, 4,

https://doi.org/10.1186/s40169-018-0182-9 (2018). Article  PubMed  PubMed Central  Google Scholar  * Yang, K. & Han, X. Lipidomics: techniques, applications, and outcomes related to

biomedical sciences. _Trends Biochem. Sci._ 41, 954–969 (2016). Article  CAS  PubMed  PubMed Central  Google Scholar  * Saliba, A. E., Vonkova, I. & Gavin, A. C. The systematic analysis

of protein-lipid interactions comes of age. _Nat. Rev. Mol. Cell Biol._ 16, 753–761 (2015). Article  CAS  PubMed  Google Scholar  * Spillantini, M. G. et al. Alpha-synuclein in Lewy bodies.

_Nature_ 388, 839–840 (1997). Article  CAS  PubMed  Google Scholar  * Jensen, P. H., Nielsen, M. S., Jakes, R., Dotti, C. G. & Goedert, M. Binding of alpha-synuclein to brain vesicles is

abolished by familial Parkinson’s disease mutation. _J. Biol. Chem._ 273, 26292–26294 (1998). Article  CAS  PubMed  Google Scholar  * den Jager, W. A. Sphingomyelin in Lewy inclusion bodies

in Parkinson’s disease. _Arch. Neurol._ 21, 615–619 (1969). Article  Google Scholar  * Burre, J., Sharma, M. & Sudhof, T. C. Definition of a molecular pathway mediating alpha-synuclein

neurotoxicity. _J. Neurosci._ 35, 5221–5232 (2015). Article  CAS  PubMed  PubMed Central  Google Scholar  * Kramer, M. L. & Schulz-Schaeffer, W. J. Presynaptic alpha-synuclein

aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. _J. Neurosci._ 27, 1405–1410 (2007). Article  CAS  PubMed  PubMed Central  Google Scholar  * Halliday, G.

M. et al. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson’s disease. _Brain_ 128, 2654–2664 (2005). Article  PubMed  Google Scholar  *

Galvagnion, C. et al. Lipid vesicles trigger alpha-synuclein aggregation by stimulating primary nucleation. _Nat. Chem. Biol._ 11, 229–234 (2015). Article  CAS  PubMed  PubMed Central 

Google Scholar  * Zhu, M., Li, J. & Fink, A. L. The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. _J. Biol. Chem._ 278,

40186–40197 (2003). Article  CAS  PubMed  Google Scholar  * Lee, H. J., Choi, C. & Lee, S. J. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the

aggregation of the cytosolic form. _J. Biol. Chem._ 277, 671–678 (2002). Article  CAS  PubMed  Google Scholar  * Grey, M. et al. Acceleration of alpha-synuclein aggregation by exosomes. _J.

Biol. Chem._ 290, 2969–2982, https://doi.org/10.1074/jbc.M114.585703 (2015). Article  CAS  PubMed  Google Scholar  * Jo, E., Fuller, N., Rand, R. P. St, George-Hyslop, P. & Fraser, P.

E. Defective membrane interactions of familial Parkinson’s disease mutant A30P alpha-synuclein. _J. Mol. Biol._ 315, 799–807 (2002). Article  CAS  PubMed  Google Scholar  * Fares, M. B. et

al. The novel Parkinson’s disease linked mutation G51D attenuates in vitro aggregation and membrane binding of alpha-synuclein, and enhances its secretion and nuclear localization in cells.

_Hum. Mol. Genet._ 23, 4491–4509 (2014). Article  CAS  PubMed  PubMed Central  Google Scholar  * Ghosh, D. et al. The newly discovered Parkinson’s disease associated Finnish mutation (A53E)

attenuates alpha-synuclein aggregation and membrane binding. _Biochem_. 53, 6419–6421 (2014). Article  CAS  Google Scholar  * Robotta, M., Cattani, J., Martins, J. C., Subramaniam, V. &

Drescher, M. Alpha-synuclein disease mutations are structurally defective and locally affect membrane binding. _J. Am. Chem. Soc._ 139, 4254–4257 (2017). Article  CAS  PubMed  Google Scholar

  * Kara, E. et al. alpha-Synuclein mutations cluster around a putative protein loop. _Neurosci. Lett._ 546, 67–70 (2013). Article  CAS  PubMed  PubMed Central  Google Scholar  * Flagmeier,

P. et al. Mutations associated with familial Parkinson’s disease alter the initiation and amplification steps of alpha-synuclein aggregation. _Proc. Natl Acad. Sci. USA_ 113, 10328–10333

(2016). Article  CAS  PubMed  PubMed Central  Google Scholar  * Cole, N. B. et al. Lipid droplet binding and oligomerization properties of the Parkinson’s disease protein alpha-synuclein.

_J. Biol. Chem._ 277, 6344–6352 (2002). Article  CAS  PubMed  Google Scholar  * Nuber, S. et al. Abrogating native alpha-synuclein tetramers in mice causes a L-DOPA-responsive motor syndrome

closely resembling Parkinson’s disease. _Neuron_ 100, 75–90 e75 (2018). Article  CAS  PubMed  PubMed Central  Google Scholar  * Fanning, S. et al. Lipidomic analysis of alpha-synuclein

neurotoxicity identifies stearoyl CoA desaturase as a target for Parkinson treatment. _Mol. Cell_ 73, 1001–1014 e1008 (2019). Article  CAS  PubMed  Google Scholar  * Burre, J. The synaptic

function of alpha-synuclein. _J. Parkinsons Dis._ 5, 699–713 (2015). Article  CAS  PubMed  PubMed Central  Google Scholar  * Scott, D. & Roy, S. alpha-Synuclein inhibits intersynaptic

vesicle mobility and maintains recycling-pool homeostasis. _J. Neurosci._ 32, 10129–10135 (2012). Article  CAS  PubMed  PubMed Central  Google Scholar  * Larsen, K. E. et al. Alpha-synuclein

overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. _J. Neurosci._ 26, 11915–11922 (2006). Article  CAS  PubMed  PubMed

Central  Google Scholar  * Nemani, V. M. et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis.

_Neuron_ 65, 66–79 (2010). Article  CAS  PubMed  PubMed Central  Google Scholar  * Busch, D. J. et al. Acute increase of alpha-synuclein inhibits synaptic vesicle recycling evoked during

intense stimulation. _Mol. Biol. Cell_ 25, 3926–3941 (2014). Article  PubMed  PubMed Central  Google Scholar  * Lautenschlager, J., Kaminski, C. F. & Kaminski Schierle, G. S.

alpha-synuclein - regulator of exocytosis, endocytosis, or both? _Trends Cell Biol._ 27, 468–479 (2017). Article  CAS  PubMed  Google Scholar  * Murphy, D. D., Rueter, S. M., Trojanowski, J.

Q. & Lee, V. M. Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. _J. Neurosci._ 20,

3214–3220 (2000). Article  CAS  PubMed  PubMed Central  Google Scholar  * Cabin, D. E. et al. Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive

stimulation in mice lacking alpha-synuclein. _J. Neurosci._ 22, 8797–8807 (2002). Article  CAS  PubMed  PubMed Central  Google Scholar  * Fusco, G. et al. Structural basis of synaptic

vesicle assembly promoted by alpha-synuclein. _Nat. Commun._ 7, 12563 (2016). Article  PubMed  PubMed Central  Google Scholar  * Georgieva, E. R., Ramlall, T. F., Borbat, P. P., Freed, J. H.

& Eliezer, D. Membrane-bound alpha-synuclein forms an extended helix: long-distance pulsed ESR measurements using vesicles, bicelles, and rodlike micelles. _J. Am. Chem. Soc._ 130,

12856–12857 (2008). Article  CAS  PubMed  PubMed Central  Google Scholar  * Nass, R. a. P., S. _Parkinson’s Disease: Molecular and Therapeutic Insights from Model Systems_ (Elsevier, 2008).

* Georgieva, E. R., Ramlall, T. F., Borbat, P. P., Freed, J. H. & Eliezer, D. The lipid-binding domain of wild type and mutant alpha-synuclein: compactness and interconversion between

the broken and extended helix forms. _J. Biol. Chem._ 285, 28261–28274 (2010). Article  CAS  PubMed  PubMed Central  Google Scholar  * Sharon, R. et al. alpha-Synuclein occurs in lipid-rich

high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. _Proc. Natl Acad. Sci. USA_ 98, 9110–9115 (2001). Article  CAS  PubMed  PubMed

Central  Google Scholar  * Mesmin, B. et al. A four-step cycle driven by PI(4)P hydrolysis directs sterol/PI(4)P exchange by the ER-Golgi tether OSBP. _Cell_ 155, 830–843 (2013). Article 

CAS  PubMed  Google Scholar  * Lev, S. Non-vesicular lipid transport by lipid-transfer proteins and beyond. _Nat. Rev. Mol. Cell Biol._ 11, 739–750 (2010). Article  CAS  PubMed  Google

Scholar  * Ouberai, M. M. et al. alpha-Synuclein senses lipid packing defects and induces lateral expansion of lipids leading to membrane remodeling. _J. Biol. Chem._ 288, 20883–20895

(2013). Article  CAS  PubMed  PubMed Central  Google Scholar  * Garten, M. et al. Methyl-branched lipids promote the membrane adsorption of alpha-synuclein by enhancing shallow lipid-packing

defects. _Phys. Chem. Chem. Phys._ 17, 15589–15597 (2015). Article  CAS  PubMed  Google Scholar  * Nuscher, B. et al. Alpha-synuclein has a high affinity for packing defects in a bilayer

membrane: a thermodynamics study. _J. Biol. Chem._ 279, 21966–21975 (2004). Article  CAS  PubMed  Google Scholar  * Kamp, F. & Beyer, K. Binding of alpha-synuclein affects the lipid

packing in bilayers of small vesicles. _J. Biol. Chem._ 281, 9251–9259 (2006). Article  CAS  PubMed  Google Scholar  * Middleton, E. R. & Rhoades, E. Effects of curvature and composition

on alpha-synuclein binding to lipid vesicles. _Biophys. J._ 99, 2279–2288 (2010). Article  CAS  PubMed  PubMed Central  Google Scholar  * Pranke, I. M. et al. alpha-Synuclein and ALPS

motifs are membrane curvature sensors whose contrasting chemistry mediates selective vesicle binding. _J. Cell Biol._ 194, 89–103 (2011). Article  CAS  PubMed  PubMed Central  Google Scholar

  * Kjaer, L., Giehm, L., Heimburg, T. & Otzen, D. The influence of vesicle size and composition on alpha-synuclein structure and stability. _Biophys. J._ 96, 2857–2870 (2009). Article 

CAS  PubMed  PubMed Central  Google Scholar  * O’Leary, E. I., Jiang, Z., Strub, M. P. & Lee, J. C. Effects of phosphatidylcholine membrane fluidity on the conformation and aggregation

of N-terminally acetylated alpha-synuclein. _J. Biol. Chem._ 293, 11195–11205 (2018). Article  PubMed  PubMed Central  Google Scholar  * Boassa, D. et al. Mapping the subcellular

distribution of alpha-synuclein in neurons using genetically encoded probes for correlated light and electron microscopy: implications for Parkinson’s disease pathogenesis. _J. Neurosci._

33, 2605–2615 (2013). Article  CAS  PubMed  PubMed Central  Google Scholar  * Chandra, S., Chen, X., Rizo, J., Jahn, R. & Sudhof, T. C. A broken alpha -helix in folded alpha-synuclein.

_J. Biol. Chem._ 278, 15313–15318 (2003). Article  CAS  PubMed  Google Scholar  * Davidson, W. S., Jonas, A., Clayton, D. F. & George, J. M. Stabilization of alpha-synuclein secondary

structure upon binding to synthetic membranes. _J. Biol. Chem._ 273, 9443–9449 (1998). Article  CAS  PubMed  Google Scholar  * Hellstrand, E. et al. Adsorption of alpha-synuclein to

supported lipid bilayers: positioning and role of electrostatics. _ACS Chem. Neurosci._ 4, 1339–1351 (2013). Article  CAS  PubMed  PubMed Central  Google Scholar  * Ferreon, A. C., Gambin,

Y., Lemke, E. A. & Deniz, A. A. Interplay of alpha-synuclein binding and conformational switching probed by single-molecule fluorescence. _Proc. Natl Acad. Sci. USA_ 106, 5645–5650

(2009). Article  CAS  PubMed  PubMed Central  Google Scholar  * Trexler, A. J. & Rhoades, E. Alpha-synuclein binds large unilamellar vesicles as an extended helix. _Biochem_. 48,

2304–2306 (2009). Article  CAS  Google Scholar  * Jao, C. C., Hegde, B. G., Chen, J., Haworth, I. S. & Langen, R. Structure of membrane-bound alpha-synuclein from site-directed spin

labeling and computational refinement. _Proc. Natl Acad. Sci. USA_ 105, 19666–19671 (2008). Article  CAS  PubMed  PubMed Central  Google Scholar  * Bussell, R. Jr. & Eliezer, D. A

structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. _J. Mol. Biol._ 329, 763–778 (2003). Article  CAS  PubMed  Google Scholar

  * Jo, E., McLaurin, J., Yip, C. M. St, George-Hyslop, P. & Fraser, P. E. alpha-Synuclein membrane interactions and lipid specificity. _J. Biol. Chem._ 275, 34328–34334 (2000). Article

  CAS  PubMed  Google Scholar  * Fusco, G. et al. Direct observation of the three regions in alpha-synuclein that determine its membrane-bound behaviour. _Nat. Commun._ 5, 3827 (2014).

Article  CAS  PubMed  Google Scholar  * Giasson, B. I., Murray, I. V., Trojanowski, J. Q. & Lee, V. M. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is

essential for filament assembly. _J. Biol. Chem._ 276, 2380–2386 (2001). Article  CAS  PubMed  Google Scholar  * Logan, T., Bendor, J., Toupin, C., Thorn, K. & Edwards, R. H.

alpha-Synuclein promotes dilation of the exocytotic fusion pore. _Nat. Neurosci._ 20, 681–689 (2017). Article  CAS  PubMed  PubMed Central  Google Scholar  * Almandoz-Gil, L. et al. In situ

proximity ligation assay reveals co-localization of alpha-synuclein and SNARE proteins in murine primary neurons. _Front. Neurol._ 9, 180, https://doi.org/10.3389/fneur.2018.00180 (2018).

Article  PubMed  PubMed Central  Google Scholar  * Lou, X., Kim, J., Hawk, B. J. & Shin, Y. K. alpha-Synuclein may cross-bridge v-SNARE and acidic phospholipids to facilitate

SNARE-dependent vesicle docking. _Biochem. J._ 474, 2039–2049 (2017). Article  CAS  PubMed  Google Scholar  * Sun, J. et al. Functional cooperation of alpha-synuclein and VAMP2 in synaptic

vesicle recycling. _Proc. Natl Acad. Sci. USA_. https://doi.org/10.1073/pnas.1903049116 (2019). Article  PubMed  PubMed Central  Google Scholar  * Atias, M. et al. Synapsins regulate

alpha-synuclein functions. _Proc. Natl Acad. Sci. USA_. https://doi.org/10.1073/pnas.1903054116 (2019). Article  PubMed  PubMed Central  Google Scholar  * Burre, J. et al. Alpha-synuclein

promotes SNARE-complex assembly in vivo and in vitro. _Science_ 329, 1663–1667 (2010). Article  CAS  PubMed  PubMed Central  Google Scholar  * Gaspar, R., Pallbo, J., Weininger, U., Linse,

S. & Sparr, E. Reprint of “Ganglioside lipids accelerate alpha-synuclein amyloid formation”. _Biochim. Biophys. Acta Proteins Proteom._ 1867, 508–518 (2019). Article  CAS  PubMed  Google

Scholar  * Bodner, C. R., Dobson, C. M. & Bax, A. Multiple tight phospholipid-binding modes of alpha-synuclein revealed by solution NMR spectroscopy. _J. Mol. Biol._ 390, 775–790

(2009). Article  CAS  PubMed  PubMed Central  Google Scholar  * Mittal, S. et al. beta2-Adrenoreceptor is a regulator of the alpha-synuclein gene driving risk of Parkinson’s disease.

_Science_ 357, 891–898 (2017). Article  CAS  PubMed  PubMed Central  Google Scholar  * Chu, Y., Dodiya, H., Aebischer, P., Olanow, C. W. & Kordower, J. H. Alterations in lysosomal and

proteasomal markers in Parkinson’s disease: relationship to alpha-synuclein inclusions. _Neurobiol. Dis._ 35, 385–398 (2009). Article  CAS  PubMed  Google Scholar  * Chatterjee, D. et al.

Proteasome-targeted nanobodies alleviate pathology and functional decline in an alpha-synuclein-based Parkinson’s disease model. _NPJ Parkinsons Dis._ 4, 25 (2018). Article  PubMed  PubMed

Central  CAS  Google Scholar  * Narayanan, V. & Scarlata, S. Membrane binding and self-association of alpha-synucleins. _Biochem_. 40, 9927–9934 (2001). Article  CAS  Google Scholar  *

Zhu, M. & Fink, A. L. Lipid binding inhibits alpha-synuclein fibril formation. _J. Biol. Chem._ 278, 16873–16877 (2003). Article  CAS  PubMed  Google Scholar  * Jo, E. et al.

Alpha-synuclein-synaptosomal membrane interactions: implications for fibrillogenesis. _Eur. J. Biochem_. 271, 3180–3189 (2004). Article  CAS  PubMed  Google Scholar  * Nakai, M. et al.

Expression of alpha-synuclein, a presynaptic protein implicated in Parkinson’s disease, in erythropoietic lineage. _Biochem. Biophys. Res. Commun._ 358, 104–110 (2007). Article  CAS  PubMed

  Google Scholar  * Renella, R., Schlehe, J. S., Selkoe, D. J., Williams, D. A. & LaVoie, M. J. Genetic deletion of the GATA1-regulated protein alpha-synuclein reduces oxidative stress

and nitric oxide synthase levels in mature erythrocytes. _Am. J. Hematol._ 89, 974–977 (2014). Article  CAS  PubMed  PubMed Central  Google Scholar  * Scherzer, C. R. et al. GATA

transcription factors directly regulate the Parkinson’s disease-linked gene alpha-synuclein. _Proc. Natl Acad. Sci. USA_ 105, 10907–10912 (2008). Article  CAS  PubMed  PubMed Central  Google

Scholar  * Abd-Elhadi, S. et al. Total and proteinase K-resistant alpha-synuclein levels in erythrocytes, determined by their ability to bind phospholipids, associate with Parkinson’s

disease. _Sci. Rep._ 5, 11120 (2015). Article  CAS  PubMed  PubMed Central  Google Scholar  * Araki, K. et al. The localization of alpha-synuclein in the process of differentiation of human

erythroid cells. _Int. J. Hematol._ 108, 130–138 (2018). Article  CAS  PubMed  Google Scholar  * Gautier, E. F. et al. Comprehensive proteomic analysis of human erythropoiesis. _Cell Rep._

16, 1470–1484 (2016). Article  CAS  PubMed  PubMed Central  Google Scholar  * Imberdis, T., Fanning, S., Newman, A., Ramalingam, N. & Dettmer, U. Studying alpha-synuclein conformation by

intact-cell cross-linking. _Methods Mol. Biol._ 1948, 77–91 (2019). Article  PubMed  Google Scholar  * Kim, S. et al. GBA1 deficiency negatively affects physiological alpha-synuclein

tetramers and related multimers. _Proc. Natl Acad. Sci. USA_ 115, 798–803 (2018). Article  CAS  PubMed  PubMed Central  Google Scholar  * Dettmer, U., Newman, A. J., von Saucken, V. E.,

Bartels, T. & Selkoe, D. KTKEGV repeat motifs are key mediators of normal alpha-synuclein tetramerization: Their mutation causes excess monomers and neurotoxicity. _Proc. Natl Acad. Sci.

USA_ 112, 9596–9601 (2015). Article  CAS  PubMed  PubMed Central  Google Scholar  * Killinger, B. A. & Moszczynska, A. Characterization of alpha-synuclein multimer stoichiometry in

complex biological samples by electrophoresis. _Anal. Chem._ 88, 4071–4084 (2016). Article  CAS  PubMed  PubMed Central  Google Scholar  * Pieri, L., Madiona, K. & Melki, R. Structural

and functional properties of prefibrillar alpha-synuclein oligomers. _Sci. Rep._ 6, 24526 (2016). Article  CAS  PubMed  PubMed Central  Google Scholar  * Luth, E. S., Bartels, T., Dettmer,

U., Kim, N. C. & Selkoe, D. J. Purification of alpha-synuclein from human brain reveals an instability of endogenous multimers as the protein approaches purity. _Biochem_. 54, 279–292

(2015). Article  CAS  Google Scholar  * Dettmer, U. et al. Loss of native alpha-synuclein multimerization by strategically mutating its amphipathic helix causes abnormal vesicle interactions

in neuronal cells. _Hum. Mol. Genet._ 26, 3466–3481 (2017). Article  CAS  PubMed  PubMed Central  Google Scholar  * Rhoades, E., Ramlall, T. F., Webb, W. W. & Eliezer, D. Quantification

of alpha-synuclein binding to lipid vesicles using fluorescence correlation spectroscopy. _Biophys. J._ 90, 4692–4700 (2006). Article  CAS  PubMed  PubMed Central  Google Scholar  * Newman,

A. J., Selkoe, D. & Dettmer, U. A new method for quantitative immunoblotting of endogenous alpha-synuclein. _PLoS ONE_ 8, e81314 (2013). Article  PubMed  PubMed Central  Google Scholar

  * Mukherjee, S. et al. Characterization and identification of dityrosine cross-linked peptides using tandem mass spectrometry. _Anal. Chem._ 89, 6136–6145 (2017). Article  CAS  PubMed 

Google Scholar  * Getoff, N. Pulse radiolysis of aromatic amino acids - state of the art. _Amino Acids_ 2, 195–214 (1992). CAS  PubMed  Google Scholar  * Papagiannakis, N. et al.

Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinson’s disease. _Neurosci. Lett._ 672, 145–149 (2018). Article  CAS  PubMed  Google

Scholar  * Wordehoff, M. M. et al. Opposed effects of dityrosine formation in soluble and aggregated alpha-synuclein on fibril growth. _J. Mol. Biol._ 429, 3018–3030 (2017). Article  PubMed

  PubMed Central  CAS  Google Scholar  * Stryer, L. & Haugland, R. P. Energy transfer: a spectroscopic ruler. _Proc. Natl Acad. Sci. USA_ 58, 719–726 (1967). Article  CAS  PubMed  PubMed

Central  Google Scholar  * Tosatto, L. et al. Single-molecule FRET studies on alpha-synuclein oligomerization of Parkinson’s disease genetically related mutants. _Sci. Rep._ 5, 16696

(2015). Article  CAS  PubMed  PubMed Central  Google Scholar  * Nath, S., Meuvis, J., Hendrix, J., Carl, S. A. & Engelborghs, Y. Early aggregation steps in alpha-synuclein as measured by

FCS and FRET: evidence for a contagious conformational change. _Biophys. J._ 98, 1302–1311 (2010). Article  CAS  PubMed  PubMed Central  Google Scholar  * Iljina, M. et al. Kinetic model of

the aggregation of alpha-synuclein provides insights into prion-like spreading. _Proc. Natl Acad. Sci. USA_ 113, E1206–E1215 (2016). Article  CAS  PubMed  PubMed Central  Google Scholar  *

Camacho, R., Tauber, D. & Scheblykin, I. G. Fluorescence anisotropy reloaded-emerging polarization microscopy methods for assessing chromophores’ organization and excitation energy

transfer in single molecules, particles, films, and beyond. _Adv. Mater._ 31, e1805671 (2019). Article  PubMed  CAS  Google Scholar  * Yamasaki, T. R. et al. Parkinson’s disease and multiple

system atrophy have distinct alpha-synuclein seed characteristics. _J. Biol. Chem._ 294, 1045–1058 (2019). Article  CAS  PubMed  Google Scholar  * Dimant, H. et al. Direct detection of

alpha synuclein oligomers in vivo. _Acta Neuropathol. Commun._ 1, 6 (2013). Article  PubMed  PubMed Central  Google Scholar  * Roberts, R. F., Wade-Martins, R. & Alegre-Abarrategui, J.

Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson’s disease brain. _Brain_ 138, 1642–1657 (2015). Article  PubMed  PubMed Central  Google

Scholar  * Betzig, E. et al. Imaging intracellular fluorescent proteins at nanometer resolution. _Science_ 313, 1642–1645 (2006). Article  CAS  PubMed  Google Scholar  * Fauvet, B. et al.

alpha-Synuclein in central nervous system and from erythrocytes, mammalian cells, and _Escherichia coli_ exists predominantly as disordered monomer. _J. Biol. Chem._ 287, 15345–15364 (2012).

Article  CAS  PubMed  PubMed Central  Google Scholar  * Alderson, T. R. & Markley, J. L. Biophysical characterization of alpha-synuclein and its controversial structure. _Intrinsically

Disord. Proteins_ 1, 18–39 (2013). Article  PubMed  Google Scholar  * Eliezer, D., Kutluay, E., Bussell, R. Jr. & Browne, G. Conformational properties of alpha-synuclein in its free and

lipid-associated states. _J. Mol. Biol._ 307, 1061–1073 (2001). Article  CAS  PubMed  Google Scholar  * Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A. & Lansbury, P. T. Jr. NACP, a

protein implicated in Alzheimer’s disease and learning, is natively unfolded. _Biochem_. 35, 13709–13715 (1996). Article  CAS  Google Scholar  * Araki, K. et al. A small-angle X-ray

scattering study of alpha-synuclein from human red blood cells. _Sci. Rep._ 6, 30473 (2016). Article  CAS  PubMed  PubMed Central  Google Scholar  * Dedmon, M. M., Lindorff-Larsen, K.,

Christodoulou, J., Vendruscolo, M. & Dobson, C. M. Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. _J. Am. Chem.

Soc._ 127, 476–477 (2005). Article  CAS  PubMed  Google Scholar  * Galvin, J. E., Schuck, T. M., Lee, V. M. & Trojanowski, J. Q. Differential expression and distribution of alpha-,

beta-, and gamma-synuclein in the developing human substantia nigra. _Exp. Neurol._ 168, 347–355 (2001). Article  CAS  PubMed  Google Scholar  * Fakhree, M. A. A., Nolten, I. S., Blum, C.

& Claessens, M. Different conformational subensembles of the intrinsically disordered protein alpha-synuclein in cells. _J. Phys. Chem. Lett._ 9, 1249–1253 (2018). Article  CAS  PubMed 

PubMed Central  Google Scholar  * Shrivastava, A. N., Aperia, A., Melki, R. & Triller, A. Physico-pathologic mechanisms involved in neurodegeneration: misfolded protein-plasma membrane

interactions. _Neuron_ 95, 33–50 (2017). Article  CAS  PubMed  Google Scholar  * Dikiy, I. et al. Semisynthetic and in vitro phosphorylation of alpha-synuclein at Y39 promotes functional

partly helical membrane-bound states resembling those induced by PD mutations. _ACS Chem. Biol._ 11, 2428–2437 (2016). Article  CAS  PubMed  PubMed Central  Google Scholar  * Anderson, V.

L., Ramlall, T. F., Rospigliosi, C. C., Webb, W. W. & Eliezer, D. Identification of a helical intermediate in trifluoroethanol-induced alpha-synuclein aggregation. _Proc. Natl Acad. Sci.

USA_ 107, 18850–18855 (2010). Article  CAS  PubMed  PubMed Central  Google Scholar  * Patterson, J. R. et al. Time course and magnitude of alpha-synuclein inclusion formation and

nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal alpha-synuclein preformed fibrils. _Neurobiol. Dis._ 130, 104525 (2019). Article  CAS  PubMed 

PubMed Central  Google Scholar  * Iyer, A. & Claessens, M. Disruptive membrane interactions of alpha-synuclein aggregates. _Biochimica et biophysica acta_. _Proteins Proteom._ 1867,

468–482 (2019). Article  CAS  Google Scholar  * Wakabayashi, K., Tanji, K., Mori, F. & Takahashi, H. The Lewy body in Parkinson’s disease: molecules implicated in the formation and

degradation of alpha-synuclein aggregates. _Neuropathol_. 27, 494–506 (2007). Article  Google Scholar  * Wakabayashi, K. et al. The Lewy body in Parkinson’s disease and related

neurodegenerative disorders. _Mol. Neurobiol._ 47, 495–508 (2013). Article  CAS  PubMed  Google Scholar  * Dale, G. E. et al. Relationships between Lewy bodies and pale bodies in Parkinson’s

disease. _Acta Neuropathol._ 83, 525–529 (1992). Article  CAS  PubMed  Google Scholar  * Gomez-Tortosa, E., Newell, K., Irizarry, M. C., Sanders, J. L. & Hyman, B. T. alpha-Synuclein

immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. _Acta Neuropathol._ 99, 352–357 (2000). Article  CAS  PubMed  Google

Scholar  * Kuusisto, E., Parkkinen, L. & Alafuzoff, I. Morphogenesis of Lewy bodies: dissimilar incorporation of alpha-synuclein, ubiquitin, and p62. _J. Neuropathol. Exp. Neurol._ 62,

1241–1253 (2003). Article  CAS  PubMed  Google Scholar  * Kanazawa, T. et al. Pale neurites, premature alpha-synuclein aggregates with centripetal extension from axon collaterals. _Brain

Pathol._ 22, 67–78 (2012). Article  PubMed  Google Scholar  * Wakabayashi, K. et al. Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and

multiple system atrophy. _Acta Neuropathol._ 96, 445–452 (1998). Article  CAS  PubMed  Google Scholar  * Soper, J. H. et al. Alpha-synuclein-induced aggregation of cytoplasmic vesicles in

_Saccharomyces cerevisiae_. _Mol. Biol. cell_ 19, 1093–1103 (2008). Article  CAS  PubMed  PubMed Central  Google Scholar  * Issidorides, M. R., Panayotacopoulou, M. T. & Tiniacos, G.

Similarities between neuronal Lewy bodies in parkinsonism and hepatic Mallory bodies in alcoholism. _Pathol. Res. Pract._ 186, 473–478 (1990). Article  CAS  PubMed  Google Scholar  * Gai, W.

P. et al. In situ and in vitro study of colocalization and segregation of alpha-synuclein, ubiquitin, and lipids in Lewy bodies. _Exp. Neurol._ 166, 324–333 (2000). Article  CAS  PubMed 

Google Scholar  * Shahmoradian, S. H. et al. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. _Nat. Neurosci._ 22, 1099–1109 (2019). Article  CAS 

PubMed  Google Scholar  * Thelen, A. M. & Zoncu, R. Emerging roles for the lysosome in lipid metabolism. _Trends Cell Biol._ 27, 833–850 (2017). Article  CAS  PubMed  PubMed Central 

Google Scholar  * Kunkle, B. W. et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Abeta, tau, immunity and lipid processing. _Nat. Genet._

51, 414–430 (2019). Article  CAS  PubMed  PubMed Central  Google Scholar  * Chang, D. et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson’s disease risk

loci. _Nat. Genet._ 49, 1511–1516 (2017). Article  CAS  PubMed  PubMed Central  Google Scholar  * Johansen, K. K., Torp, S. H., Farrer, M. J., Gustavsson, E. K. & Aasly, J. O. A case of

Parkinson’s disease with no Lewy body pathology due to a homozygous exon deletion in Parkin. _Case Rep. Neurol. Med._ 2018, 6838965 (2018). PubMed  PubMed Central  Google Scholar  *

Haberkant, P. & Holthuis, J. C. Fat & fabulous: bifunctional lipids in the spotlight. _Biochim. Biophys. Acta_ 1841, 1022–1030 (2014). Article  CAS  PubMed  Google Scholar  *

Hoglinger, D. et al. Trifunctional lipid probes for comprehensive studies of single lipid species in living cells. _Proc. Natl Acad. Sci. USA_ 114, 1566–1571 (2017). Article  PubMed  CAS 

PubMed Central  Google Scholar  * Zunke, F. et al. Reversible conformational conversion of alpha-synuclein into toxic assemblies by glucosylceramide. _Neuron_ 97, 92–107 e110 (2018). Article

  CAS  PubMed  Google Scholar  Download references AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, 60612, USA

Bryan A. Killinger & Jeffrey H. Kordower * CEA and Laboratory of Neurodegenerative Diseases, Institut Francois Jacob (MIRCen), CNRS, 92265, Fontenay-Aux-Roses cedex, France Ronald Melki

* Center for Neurodegenerative Science, Van Andel Research Institute, Grand Rapids, MI, 49503, USA Patrik Brundin Authors * Bryan A. Killinger View author publications You can also search

for this author inPubMed Google Scholar * Ronald Melki View author publications You can also search for this author inPubMed Google Scholar * Patrik Brundin View author publications You can

also search for this author inPubMed Google Scholar * Jeffrey H. Kordower View author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS B.A.K. and J.H.K.

conceived and prepared the manuscript. R.M. and P.B. provided valuable discussion, as well as reviewed and edited the manuscript. CORRESPONDING AUTHOR Correspondence to Jeffrey H. Kordower.

ETHICS DECLARATIONS COMPETING INTERESTS P.B. has received commercial support as a consultant from Axial Biotherapeutics, CuraSen, Fujifilm-Cellular Dynamics International, IOS Press

Partners, LifeSci Capital, and Living Cell Technologies Ltd. He has received commercial support for grants/research from Lundbeck A/S and Roche. He has ownership interests in Acousort AB and

Axial Biotherapeutics and is on the steering committee of the NILO-PD trial. J.H.K. has received commercial support as a consultant from Cellular Dynamics International, Inc., Michael J.

Fox Foundation, Abbvie, Exicure, NSGENE, Guidepoint, Inhibikhase, Axovant, and Seelos B.A.K. and R.M. have no competing interests to disclose. ADDITIONAL INFORMATION PUBLISHER’S NOTE

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under a

Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit

to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are

included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and

your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this

license, visit http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Killinger, B.A., Melki, R., Brundin, P. _et al._ Endogenous

alpha-synuclein monomers, oligomers and resulting pathology: let’s talk about the lipids in the room. _npj Parkinsons Dis._ 5, 23 (2019). https://doi.org/10.1038/s41531-019-0095-3 Download

citation * Received: 23 July 2019 * Accepted: 09 October 2019 * Published: 12 November 2019 * DOI: https://doi.org/10.1038/s41531-019-0095-3 SHARE THIS ARTICLE Anyone you share the following

link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature

SharedIt content-sharing initiative